Digestive System Disease Clinical Trial
— PREMABDOOfficial title:
Impact Assessment of Abdominal Massage on the Feeding Tolerance of Preterms (Less Than 34 Weeks of Amenorrhea) : a Randomized, Single-blind Controlled Trial
Verified date | January 2024 |
Source | University Hospital, Clermont-Ferrand |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Every year in France, 60,000 children are born prematurely (before 37 weeks of amenorrhea - WA), and present an immaturity of their various systems, in particular the digestive system. This can result in feeding intolerance, expressed by abdominal distension, regurgitation, irregular transit and abdominal discomfort. It can influence the length of hospitalization and lead to necrotising enterocolitis, a major complication. At the Clermont-Ferrand University Hospital Center, abdominal massages have been performed by physiotherapist for several years in order to improve the state of the digestive system of preterm infants. The indication for abdominal massages are very dependent on the caregivers in charge of the newborns because the evaluation of feeding intolerance remains subjective. In this context, the investigators carried out a first study to validate a scale that they created (ECAP scale : Clinical Assessment Scale for Abdominal state of Preterm infant) to assess in a rapid, reliable and reproductible manner the abdominal state of preterm infant - data currently being published). This scale can pose the indications for abdominal massage more objectively. The hypothesis is that abdominal massage improves feeding tolerance (decrease ECAP score), allows faster weight gain and reaching the full ration and therefore reduces the length of hospitalization of preterm infants. The aim of the study is to assess the effectiveness of abdominal massage, over a period of 14 days, on the feeding tolerance of preterm infants (under 34 weeks of amenorrhea), defined by the achievement and maintenance of an ECAP score less than 4 during 3 days.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | June 2026 |
Est. primary completion date | February 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 3 Days to 60 Days |
Eligibility | Inclusion Criteria: - Newborn, premature, less than 34 Weeks of Amennorhea - at least 3 days of life - hospitalized in neonatal intensive care units - with feeding intolerance demonstrated by an ECAP (Clinical Abdominal Assessement scale for preterms) score equal to or greater than 4/20 - whose holders of parental authority are able to give free and informed consent to participate in this study. Exclusion Criteria: - premature newborns with a congenital pathology such as malformation, genetic or chromosomal abnormality - newborns whose holders of parental authority are protected by law (under guardianship, curatorship, placed under judicial safeguard) or aged under 18 - rejection of participation by parents - newborns with a contraindication to abdominal massage (fever, major hemodynamic instability) |
Country | Name | City | State |
---|---|---|---|
France | CHU clermont-ferrand | Clermont-Ferrand |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Clermont-Ferrand |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical Abdominal assessment scale for Preterm infants score (ECAP score) | score between 0 and 20 | twice day during 14 days | |
Secondary | Variation of the ECAP score (Clinical Abdominal assessement scale for preterms score) between t0 minute and t10 minutes | score between 0 and 20 | up to 14 days | |
Secondary | Weight gain of preterm infants with feeding intolerance | Daily weight of preterm infants, in z-score | up to 28 days | |
Secondary | Duration to reach the full ration | Number of days needed to reach the full ration (120mL/kg/day) | up to 28 days | |
Secondary | Duration of hospitalization in level 3 | Total number of days of hospitalization in level 3 | up to 3 months | |
Secondary | 6-hour fasting windows | Number of 6-hour fasting windows | up to 28 days | |
Secondary | Incidence of occurrence of necrotizing enterocolitis | number of necrotizing enterocolitis | up to 28 days | |
Secondary | Evolution of digestive tolerance over time | Raw ECAP value at t10 minutes over time | up to 28 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05066139 -
Multidisciplinary Evaluation of Elderly Patients With Digestive Cancer (EPODIG-G)
|
N/A | |
Recruiting |
NCT04475952 -
Early Diagnosis of Upper Digestive Tract Disease
|
||
Completed |
NCT05064163 -
SROI Project on the Surgical Waiting List Management System
|
||
Completed |
NCT03559543 -
Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma
|
Phase 2 | |
Completed |
NCT03549494 -
Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction
|
Phase 2 | |
Completed |
NCT03723447 -
Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)
|
Phase 4 | |
Enrolling by invitation |
NCT01483248 -
Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis
|
Phase 1/Phase 2 | |
Completed |
NCT03008460 -
Efficacy, Safety and Tolerability of Eziclen®/Izinova® Versus Klean-prep® on Bowel Cleansing in Adolescents Undergoing Colonoscopy
|
Phase 3 | |
Active, not recruiting |
NCT05253859 -
CFTR Modulators and Gastrointestinal Complications
|
||
Not yet recruiting |
NCT05636657 -
Comparative Study of Intestinal Color Ultrasound and Capsule Endoscopy in Monitoring Crohn's Disease
|
||
Completed |
NCT05160077 -
Optoacoustic Characterization of Postprandial Intestinal Blood Flow
|
N/A | |
Recruiting |
NCT05401058 -
Low-dose Droperidol for Prevention of Postoperative Delirium in Elderly Patients After Non-cardiac Surgery
|
N/A | |
Completed |
NCT06283732 -
A Clinical Study to Assess the Effect of a Supplement on Digestive Health, Overall Well-being, and Participant Experience.
|
N/A | |
Not yet recruiting |
NCT06271538 -
Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome
|
Phase 4 | |
Terminated |
NCT03594331 -
Gastric Gluten-Degradation Activity of PvP001
|
Phase 1 | |
Not yet recruiting |
NCT05405842 -
Transauricular Vagal Nerve Stimulation; Functional Dyspepsia and Gastroparesis
|
N/A | |
Completed |
NCT02785783 -
Endorings™ Assisted Colonoscopy Versus Standard Colonoscopy for Polyp Detection
|
N/A | |
Completed |
NCT00072943 -
A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease
|
Phase 2 | |
Completed |
NCT03037385 -
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT05827679 -
Creation and Validation of a Clinical Evaluation Scale for Abdominal Condition of the Premature (ECAP)
|